We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+9.67%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$98.6B
AUM Growth
+$9.82B
Cap. Flow
+$3.18B
Cap. Flow %
3.23%
Top 10 Hldgs %
34.51%
Holding
3,532
New
899
Increased
935
Reduced
953
Closed
698

Top Buys

Rank Stock Value
1
IVV icon
iShares Core S&P 500 ETF
IVV
+$3.93B
2
MSFT icon
Microsoft
MSFT
+$556M
3
COR icon
Cencora
COR
+$492M
4
NFLX icon
Netflix
NFLX
+$452M
5
BAC icon
Bank of America
BAC
+$411M

Sector Composition

Rank Sector Weight
1 Technology 20.19%
2 Consumer Discretionary 12.64%
3 Healthcare 9.35%
4 Financials 8.34%
5 Communication Services 6.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NNNN
2301
Anbio Biotechnology
NNNN
$509M
$389K ﹤0.01%
+10,443
New +$469K
U icon
2302
CALL
Unity
U
$14B
$388K ﹤0.01%
+9,700
New +$360K
SLRC icon
2303
SLR Investment Corp
SLRC
$704M
$388K ﹤0.01%
+25,364
New +$412K
MSTR icon
2304
Strategy Inc
MSTR
$34.1B
$388K ﹤0.01%
+1,203
New +$446K
NUTR
2305
Nusatrip Inc
NUTR
$386K ﹤0.01%
+48,325
New +$255K
BTM
2306
DELISTED
Bitcoin Depot
BTM
$385K ﹤0.01%
16,375
-99,072
-86% -$3.1M
TGLS icon
2307
Tecnoglass
TGLS
$1.99B
$385K ﹤0.01%
5,751
-28,657
-83% -$2.11M
GPI icon
2308
Group 1 Automotive
GPI
$4.26B
$383K ﹤0.01%
875
-4,281
-83% -$1.92M
RXRX icon
2309
Recursion Pharmaceuticals
RXRX
$1.58B
$382K ﹤0.01%
78,259
-8,053
-9% -$42.3K
LSGR icon
2310
Natixis Loomis Sayles Focused Growth ETF
LSGR
$823M
$381K ﹤0.01%
+8,577
New +$369K
VALN
2311
Valneva
VALN
$518M
$381K ﹤0.01%
+31,211
New +$267K
LEGH icon
2312
Legacy Housing
LEGH
$629M
$380K ﹤0.01%
+13,823
New +$352K
ENS icon
2313
EnerSys
ENS
$6.43B
$380K ﹤0.01%
+3,361
New +$330K
IOBT
2314
DELISTED
IO Biotech
IOBT
$379K ﹤0.01%
1,052,631
-1,052,631
-50% -$1.81M
TWIN icon
2315
Twin Disc
TWIN
$321M
$378K ﹤0.01%
27,105
+6,046
+29% +$65.4K
SMFG icon
2316
Sumitomo Mitsui Financial
SMFG
$159B
$376K ﹤0.01%
+22,486
New +$360K
BX icon
2317
PUT
Blackstone
BX
$104B
$376K ﹤0.01%
2,200
-197,800
-99% -$33.9M
FSBC icon
2318
Five Star Bancorp
FSBC
$1.01B
$376K ﹤0.01%
11,671
-6,180
-35% -$194K
RSKD icon
2319
Riskified
RSKD
$719M
$375K ﹤0.01%
80,130
-210,991
-72% -$1.04M
NEOV icon
2320
NeoVolta
NEOV
$108M
$373K ﹤0.01%
+83,590
New +$370K
URGN icon
2321
UroGen Pharma
URGN
$1.97B
$373K ﹤0.01%
18,675
-1,985
-10% -$35.6K
EQBK icon
2322
Equity Bancshares
EQBK
$1.04B
$372K ﹤0.01%
+9,146
New +$370K
MDWD icon
2323
MediWound
MDWD
$184M
$372K ﹤0.01%
20,651
+4,309
+26% +$79.5K
ENPH icon
2324
CALL
Enphase Energy
ENPH
$4.62B
$372K ﹤0.01%
+10,500
New +$390K
PDD icon
2325
CALL
Pinduoduo
PDD
$126B
$370K ﹤0.01%
2,800
-6,900
-71% -$817K

Similar funds

Marshall Wace's Q3 2025 Portfolio in Review

As of Q3 2025, Marshall Wace held 3,532 positions worth $98.6B, up 11% from $88.8B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Marshall Wace deployed $3.18B of net new capital in Q3 2025, opening 899 new positions and adding to 935 existing holdings. Its largest new stake was Texas Instruments: 1,537,539 shares worth $282M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $636M trimmed.

  • Marshall Wace's largest Q3 2025 buy was Texas Instruments: 1,537,539 shares worth $282M.
  • Marshall Wace added most to iShares Core S&P 500 ETF in Q3 2025, an estimated $3.93B increase.
  • Marshall Wace's biggest Q3 2025 reduction was Alphabet (Google) Class A, cutting an estimated $636M.
  • Marshall Wace fully exited AT&T in Q3 2025, selling an estimated $235M.
  • Marshall Wace's ten largest holdings make up 35% of its $98.6B portfolio in Q3 2025.
  • Marshall Wace opened 899 new positions and closed 698 in Q3 2025.
  • Marshall Wace's portfolio value rose 11% quarter-over-quarter to $98.6B.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.